Sinew Pharma Inc. (TPEX:6634)

Sinew Pharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	0.33	6.23	0.46
Revenue Growth (YoY)	-	-	-	-94.73%	1248.27%	-
Cost of Revenue	-	-	-	0.04	1.14	0.14
Gross Profit	-	-	-	0.29	5.09	0.32
Selling, General & Admin	40.28	36.95	34.75	34.1	26.77	17.73
Research & Development	119.39	131.91	151.51	114.62	72.75	66.71
Operating Expenses	159.67	168.86	186.25	148.72	99.51	84.43
Operating Income	-159.67	-168.86	-186.25	-148.43	-94.42	-84.11
Interest Expense	-0.2	-0.41	-0.78	-0.28	-0.15	-0.27
Interest & Investment Income	16.5	16.66	16.03	8.37	2.95	2.37
Other Non Operating Income (Expenses)	1.46	2.25	0.08	0.15	0.04	0
Pretax Income	-141.91	-150.37	-170.92	-140.18	-91.58	-82.01
Net Income	-141.91	-150.37	-170.92	-140.18	-91.58	-82.01
Net Income to Common	-141.91	-150.37	-170.92	-140.18	-91.58	-82.01
Shares Outstanding (Basic)	71	71	70	69	59	50
Shares Outstanding (Diluted)	71	71	70	69	59	50
Shares Change (YoY)	0.55%	1.21%	1.68%	16.47%	19.41%	30.28%
EPS (Basic)	-1.99	-2.11	-2.43	-2.02	-1.54	-1.65
EPS (Diluted)	-1.99	-2.11	-2.43	-2.02	-1.54	-1.65
Free Cash Flow	-97.47	-106.26	-125.26	-98.99	-59.5	-61.06
Free Cash Flow Per Share	-1.37	-1.49	-1.78	-1.43	-1.00	-1.23
Gross Margin	-	-	-	88.41%	81.75%	70.13%
Operating Margin	-	-	-	-45252.44%	-1515.81%	-18204.76%
Profit Margin	-	-	-	-42737.81%	-1470.14%	-17751.30%
Free Cash Flow Margin	-	-	-	-30178.66%	-955.19%	-13217.10%
EBITDA	-137.5	-144.98	-163.63	-128.29	-73.88	-64.41
D&A For EBITDA	22.17	23.88	22.62	20.13	20.55	19.7
EBIT	-159.67	-168.86	-186.25	-148.43	-94.42	-84.11

Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.